{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:00:23Z","timestamp":1761559223034,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmig.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Minimally Invasive Gynecology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jmig.2023.10.015","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T04:12:17Z","timestamp":1697775137000},"page":"21-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safely Introducing New Surgical Devices in Minimally Invasive Gynecologic Surgery: An Argument for Use of the IDEAL Framework"],"prefix":"10.1016","volume":"31","author":[{"given":"Aparna","family":"Ramanathan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelby","family":"Davis-Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl B.","family":"Iglesia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmig.2023.10.015_bib0001","unstructured":"US Food and Drug Administration. What we do. 2018. Available at: https:\/\/www.fda.gov\/about-fda\/what-we-do Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0033","unstructured":"US Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA activities related to the ongoing post-market review of Essure and FDA's commitment to keep women informed. 2018. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/statement-fda-commissioner-scott-gottlieb-md-fda-activities-related-ongoing-post-market-review Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0003","unstructured":"US Food and Drug Administration. Classify your medical device. Available at: https:\/\/www.fda.gov\/medical-devices\/overview-device-regulation\/classify-your-medical-device Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0002","first-page":"128","article-title":"Left to their own devices: how the dangers of power morcellators went undetected by FDA for two decades","volume":"74","author":"Godina","year":"2019","journal-title":"Food Law J"},{"key":"10.1016\/j.jmig.2023.10.015_bib0036","unstructured":"US Food and Drug Administration. How to study and market your device. Available at: https:\/\/www.fda.gov\/medical-devices\/device-advice-comprehensive-regulatory-assistance\/how-study-and-market-your-device Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0037","unstructured":"US Food and Drug Administration. Evaluation of automatic Class III designation (de novo) summaries. Available at: https:\/\/www.fda.gov\/about-fda\/cdrh-transparency\/evaluation-automatic-class-iii-designation-de-novo-summaries Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0005","unstructured":"US Food and Drug Administration. PMA application contents. Available at: https:\/\/www.fda.gov\/medical-devices\/premarket-approval-pma\/pma-application-contents Accessed October 14, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0004","unstructured":"US Food and Drug Administration. Premarket approval (PMA). Available at: https:\/\/www.fda.gov\/medical-devices\/premarket-submissions-selecting-and-preparing-correct-submission\/premarket-approval-pma Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0006","unstructured":"US Food and Drug Administration. PMA review process. Available at: https:\/\/www.fda.gov\/medical-devices\/premarket-approval-pma\/pma-review-process Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0038","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jmig.2013.12.003","article-title":"Laparoscopic morcellator-related complications","volume":"21","author":"Milad","year":"2014","journal-title":"J Minim Invasive Gynecol"},{"key":"10.1016\/j.jmig.2023.10.015_bib0007","unstructured":"Obstetrics and Gynecology Devices Advisory Committee. FDA executive summary: laparoscopic power morcellation during uterine surgery for fibroids. Prepared for the July 10-11, 2014 meeting. Available at: https:\/\/wayback.archive-it.org\/7993\/20170113091521\/https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/MedicalDevices\/MedicalDevicesAdvisoryCommittee\/ObstetricsandGynecologyDevices\/UCM404148.pdf Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0039","unstructured":"US Food and Drug Administration. Reporting allegations of regulatory misconduct. Available at: https:\/\/www.fda.gov\/medical-devices\/medical-device-safety\/reporting-allegations-regulatory-misconduct Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0008","first-page":"471","article-title":"Electrical cutting device for laparoscopic removal of tissue from the abdominal cavity","volume":"81","author":"Steiner","year":"1993","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jmig.2023.10.015_bib0009","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1074-3804(98)80092-3","article-title":"Laparoscopic supracervical hysterectomy with a new disposable morcellator","volume":"5","author":"Kresch","year":"1998","journal-title":"J Am Assoc Gynecol Laparosc"},{"key":"10.1016\/j.jmig.2023.10.015_bib0010","article-title":"Fibroid surgery puts doctor fighting cancer diagnosis in spotlight: during routine procedure doctors find rare cancer, which procedure might have spread","author":"Levitz","year":"2013","journal-title":"The Wall Street Journal"},{"key":"10.1016\/j.jmig.2023.10.015_bib0011","unstructured":"The Cancer Letter. Amy Reed, physician and patient who \u2018moved mountains\u2019 to end widespread use of power morcellation, dies at 44. 2017. Available at: https:\/\/cancerletter.com\/the-cancer-letter\/20170526_1\/Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0012","unstructured":"Grady D. Amy Reed, doctor who fought a risky medical procedure, dies at 44. The New York Times. Available at: https:\/\/www.nytimes.com\/2017\/05\/24\/us\/amy-reed-died-cancer-patient-who-fought-morcellation-procedure.html Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0013","unstructured":"US Food and Drug Administration. Laparoscopic uterine power morcellation in hysterectomy and myomectomy: FDA safety communication. Available at: https:\/\/wayback.archive-it.org\/7993\/20170406071822\/https:\/\/www.fda.gov\/MedicalDevices\/Safety\/AlertsandNotices\/ucm393576.htm Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0014","unstructured":"US Food and Drug Administration. UPDATED laparoscopic uterine power morcellation in hysterectomy and myomectomy: FDA safety communication. Available at: https:\/\/wayback.archive-it.org\/7993\/20170404182209\/https:\/\/www.fda.gov\/MedicalDevices\/Safety\/AlertsandNotices\/ucm424443.htm Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0015","unstructured":"US Food and Drug Administration. The FDA recommends performing contained morcellation in women when laparoscopic power morcellation is appropriate. Available at: https:\/\/www.fda.gov\/medical-devices\/safety-communications\/update-fda-recommends-performing-contained-morcellation-women-when-laparoscopic-power-morcellation Accessed January 10, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0016","unstructured":"US Food and Drug Administration. Perform only contained morcellation when power morcellation is appropriate: FDA safety communication. Available at: https:\/\/www.fda.gov\/medical-devices\/safety-communications\/update-perform-only-contained-morcellation-when-laparoscopic-power-morcellation-appropriate-fda Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0042","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1097\/AOG.0000000000004291","article-title":"Uterine Morcellation for Presumed Leiomyomas: ACOG Committee Opinion, Number 822","volume":"137","year":"2021","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jmig.2023.10.015_bib0040","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jmig.2018.03.010","article-title":"Electronic address: generalmail@aagl.org. Morcellation during uterine tissue extraction: an update","volume":"25","year":"2018","journal-title":"J Minim Invasive Gynecol"},{"key":"10.1016\/j.jmig.2023.10.015_bib0017","unstructured":"Schwab N, Chaudhuri S. Bayer to buy Conceptus. The Wall Street Journal. Available at: https:\/\/www.wsj.com\/articles\/SB10001424127887323528404578452442114976204 Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0018","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.fertnstert.2009.02.080","article-title":"Hysteroscopic tubal sterilization: a systematic review of the Essure system","volume":"94","author":"Hurskainen","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jmig.2023.10.015_bib0019","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jmig.2014.03.019","article-title":"Management of complications encountered with Essure hysteroscopic sterilization: a systematic review","volume":"21","author":"Adelman","year":"2014","journal-title":"J Minim Invasive Gynecol"},{"key":"10.1016\/j.jmig.2023.10.015_bib0020","unstructured":"Bayer. Essure permanent birth control: instructions for use. 2002. Available at: https:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/essure_ifu.pdf Accessed October 14, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0021","unstructured":"US Food and Drug Administration. Summary of safety and effectiveness data: EssureTM system. 2002. Available at: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf2\/p020014b.pdf Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0022","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1056\/NEJMp1510514","article-title":"Revisiting Essure - toward safe and effective sterilization","volume":"373","author":"Dhruva","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmig.2023.10.015_bib0023","unstructured":"Bayer Healthcare. Essure system for permanent birth control: executive summary for the FDA advisory committee meeting. 2015. Available at: https:\/\/www.fdanews.com\/ext\/resources\/files\/09-15\/092815-bayer-materials.pdf?1442940661 Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0024","unstructured":"US Food and Drug Administration. Post-approval studies (PAS) database: newly trained. Physicians Press. Available at:https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfPMA\/pma_pas.cfm?t_id=90320&c_id=23 Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0025","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jmig.2017.06.021","article-title":"Algorithm of transvaginal ultrasound and\/or hysterosalpingogram for confirmation testing at 3 months after Essure placement","volume":"24","author":"Vleugels","year":"2017","journal-title":"J Minim Invasive Gynecol"},{"key":"10.1016\/j.jmig.2023.10.015_bib0026","unstructured":"US Food and Drug Administration. Problems reported with Essure. 2022. Available at: https:\/\/www.fda.gov\/medical-devices\/essure-permanent-birth-control\/problems-reported-essure Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0027","unstructured":"Facebook. Essure problems. Available at: https:\/\/www.facebook.com\/groups\/Essureproblems Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0028","unstructured":"US Food and Drug Administration. FDA review document: review of the Essure system for hysteroscopic sterilization. Available at:https:\/\/wayback.archive-it.org\/7993\/20170723124202\/https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/MedicalDevices\/MedicalDevicesAdvisoryCommittee\/ObstetricsandGynecologyDevices\/UCM463486.pdf Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0029","unstructured":"US Food and Drug Administration. FDA takes additional action to better understand safety of Essure, inform patients of potential risks. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-takes-additional-action-better-understand-safety-essure-inform-patients-potential-risks Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0030","unstructured":"US Food and Drug Administration. Labeling for permanent hysteroscopically-placed tubal implants intended for sterilization: guidance for industry and Food and Drug Administration staff. 2016. Available at: https:\/\/www.fda.gov\/media\/96315\/download Accessed October 5, 2023."},{"key":"10.1016\/j.jmig.2023.10.015_bib0032","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(17)32548-5","article-title":"Contraception implant removed from global market","volume":"390","author":"Casassus","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jmig.2023.10.015_bib0034","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(09)61116-8","article-title":"No surgical innovation without evaluation: the IDEAL recommendations","volume":"374","author":"McCulloch","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jmig.2023.10.015_bib0035","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/SLA.0000000000002794","article-title":"No surgical innovation without evaluation: evolution and further development of the IDEAL framework and recommendations","volume":"269","author":"Hirst","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.jmig.2023.10.015_bib0041","unstructured":"US Food and Drug Administration. 522 Postmarket Studies Surveillance Database: Essure system for permanent birth control. Available at:https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfPMA\/pss.cfm?t_id=356&c_id=3854 Accessed October 5, 2023."}],"container-title":["Journal of Minimally Invasive Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553465023009196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553465023009196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:46:37Z","timestamp":1761558397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553465023009196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1553465023009196"],"URL":"https:\/\/doi.org\/10.1016\/j.jmig.2023.10.015","relation":{},"ISSN":["1553-4650"],"issn-type":[{"type":"print","value":"1553-4650"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safely Introducing New Surgical Devices in Minimally Invasive Gynecologic Surgery: An Argument for Use of the IDEAL Framework","name":"articletitle","label":"Article Title"},{"value":"Journal of Minimally Invasive Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmig.2023.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AAGL. All rights reserved.","name":"copyright","label":"Copyright"}]}}